The Met receptor tyrosine kinase binds to, and is activated by, its specific ligand, the growth and motility factor HGF/SF (hepatocyte growth factor/scatter factor).
HGF/SF shares its overall domain structure with proteinases of the plasminogen family; the domain structure of Met is unique and its extracellular sequence is related to semaphorins and the semaphorin receptors (plexins).
Met activation results in tyrosine phosphorylation of the receptor at a unique bidentate docking site in the carboxy-terminal end of Met, which recruits signalling molecules such as the scaffolding adaptor Gab1 (growth-factor-receptor-bound protein 2 (Grb2)-associated binder 1). Gab1 mediates most of the complex cellular responses to Met activation.
The juxtamembrane domain of Met contains an additional docking site that, when phosphorylated, recruits Cbl, a ubiquitin ligase, which results in Met ubiquitylation, endocytosis and degradation.
Met activation can induce proliferation, dissociation of epithelial cells (scattering) and motility. Furthermore, signals from Met elicit a complex morphogenic response — the formation of branched tubules from epithelial cells grown in a collagen matrix.
During development, Met and HGF/SF are essential for the growth and survival of epithelial cell types and for migration of muscle progenitors. In adult physiology, Met activity prevents tissue damage and enhances liver regeneration.
Met is activated in human cancer by several molecular mechanisms, for example: mutations that alter the sequence and activity of the kinase domain; by overexpression; or by simultaneous expression of receptor and ligand, which results in the autocrine stimulation of cancer cells.
Met and HGF/SF are important targets for cancer therapy and many efforts are directed towards the identification of inhibitors that are active in vivo.
Hepatocyte growth factor/scatter factor and its receptor, the tyrosine kinase Met, arose late in evolution and are unique to vertebrates. In spite of this, Met uses molecules such as Gab1 — homologues of which are present in Caenorhabditis elegans and Drosophila melanogaster — for downstream signalling. Pivotal roles for Met in development and cancer have been established: Met controls cell migration and growth in embryogenesis; it also controls growth, invasion and metastasis in cancer cells; and activating Met mutations predispose to human cancer.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Cooper, C. S. et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature 311, 29–33 (1984).
Park, M. et al. Mechanism of met oncogene activation. Cell 45, 895–904 (1986). Early molecular characterization of the Tpr–Met oncogene and the Met proto-oncogene.
Stoker, M., Gherardi, E., Perryman, M. & Gray, J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 327, 239–242 (1987). Reports the characterization of a fibroblast-derived protein which causes 'scattering' of epithelial cells (scatter factor). The report describes the isolation of the factor from fibroblasts and establishes its paracrine mechanism of action.
Nakamura, T. et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 342, 440–443 (1989).
Miyazawa, K. et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun. 163, 967–973 (1989).
Zarnegar, R. & Michalopoulos, G. Purification and biological characterization of human hepatopoietin A, a polypeptide growth factor for hepatocytes. Cancer Res. 49, 3314–3320 (1989). References 4–6 report the purification of hepatocyte growth factor (HGF) and the cloning and sequencing of HGF cDNA. These papers established that the two chains of HGF are encoded by a single transcript and that HGF contains kringle domains and an inactive serine proteinase domain.
Weidner, K. M. et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc. Natl Acad. Sci. USA 88, 7001–7005 (1991).
Gherardi, E. & Stoker, M. Hepatocytes and scatter factor. Nature 346, 228 (1990).
Bottaro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802–804 (1991).
Donate, L. E. et al. Molecular evolution and domain structure of plasminogen-related growth factors (HGF/SF and HGF1/MSP). Protein Sci. 3, 2378–2394 (1994).
Gherardi, E. et al. Functional map and domain structure of the MET (HGF/SF) receptor. Proc. Natl Acad. Sci. USA 100, 12039–12044 (2003). A mutagenesis study of the extracellular part of Met that maps HGF/SF binding to the sema domain. The study also provides three-dimensional models of the sema and Ig domains of Met.
Ponzetto, C. et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 77, 261–271 (1994). The bidentate docking site in the carboxy-terminal domain of Met is identified. Phosphorylation of this site allows interactions with multiple SH2-domain-containing signal transducers, and its mutation results in loss of signalling function of Met.
Weidner, K. M. et al. Interaction between gab1 and the c met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 384, 173–176 (1996).
Sachs, M. et al. Essential role of Gab1 for signaling by the c-Met receptor in vivo. J. Cell Biol. 150, 1375–1384 (2000). A study of the genetic analysis of Gab1 by targeted mutagenesis in mice. Remarkably similar phenotypes of the Gab1 and Met mutations are reported, which shows the essential role of Gab1 in Met signalling.
Montesano, R., Matsumoto, K., Nakamura, T. & Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell 67, 901–908 (1991).
Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699–702 (1995).
Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702–705 (1995).
Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768–771 (1995). Limb muscles develop from cells that migrate from the somites. The authors report here that in Met-homozygous-mutant-mouse embryos, myogenic precursor cells do not invade the limb buds and, as a consequence, skeletal muscles of the limbs do not form. By contrast, development of the paraxial skeletal muscles proceeds in the absence of Met.
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68–73 (1997). Hereditary papillary renal carcinoma is a form of kidney cancer that is characterized by a predisposition to develop multiple, renal tumours. Here, the first missense mutations in Met in hereditary tumours — papillary renal carcinomas — and in sporadic forms of renal cancer are identified.
Lokker, N. A. et al. Structure–function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 11, 2503–2510 (1992).
Schwall, R. H. et al. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J. Cell Biol. 133, 709–718 (1996).
Hartmann, G. et al. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 8, 125–134 (1998).
DiGabriele, A. D. et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393, 812–817 (1998).
Ultsch, M., Lokker, N. A., Godowski, P. J. & de Vos, A. M. Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution. Structure 6, 1383–1393 (1998).
Chirgadze, D. Y. et al. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nature Struct. Biol. 6, 72–79 (1999).
Lietha, D., Chirgadze, D. Y., Mulloy, B., Blundell, T. L. & Gherardi, E. Crystal structures of NK1–heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 20, 5543–5555 (2001). A crystallographic analysis of the NK1 fragment of HGF/SF in complex with heparin. The study defines the heparin-binding site in the amino-terminal domain and provides the basis for engineering NK1 variants with full agonistic activity.
Lokker, N. A., Presta, L. G. & Godowski, P. J. Mutational analysis and molecular modeling of the N-terminal kringle-containing domain of hepatocyte growth factor identifies amino acid side chains important for interaction with the c-Met receptor. Protein Eng. 7, 895–903 (1994).
Xiong, J. P. et al. Crystal structure of the extracellular segment of integrin αVβ3 in complex with an Arg-Gly-Asp ligand. Science 296, 151–155 (2002).
Leonard, E. J. & Danilkovitch, A. Macrophage stimulating protein. Adv. Cancer. Res. 77, 139–167 (2000).
Raabe, T. et al. DOS, a novel pleckstrin homology domain-containing protein required for signal transduction between sevenless and Ras1 in Drosophila. Cell 85, 911–920 (1996).
Schutzman, J. L. et al. The Caenorhabditis elegans EGL-15 signaling pathway implicates a DOS-like multisubstrate adaptor protein in fibroblast growth factor signal transduction. Mol. Cell. Biol. 21, 8104–8116 (2001). References 30 and 31 report the identification of the Drosophila and C. elegans Gab homologues, Dos and Soc1, and show the requirement for these genes in the signalling of receptor tyrosine kinases.
Lock, L. S., Royal, I., Naujokas, M. A. & Park, M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and-independent recruitment of Gab1 to receptor tyrosine kinases. J. Biol. Chem. 275, 31536–31545 (2000).
Stefan, M. et al. Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis. J. Biol. Chem. 276, 3017–3023 (2001).
Sachs, M. et al. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J. Cell Biol. 133, 1095–1107 (1996).
Maroun, C. R. et al. The Gab1 PH domain is required for localization of Gab1 at sites of cell–cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol. Cell. Biol. 19, 1784–1799 (1999).
Schaeper, U. et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J. Cell Biol. 149, 1419–1432 (2000).
Gu, H. & Neel, B. G. The 'Gab' in signal transduction. Trends Cell Biol. 13, 122–130 (2003).
Rosario, M. & Birchmeier, W. How to make tubes: signaling by the Met receptor tyrosine kinase. Trends Cell Biol. 13, 328–335 (2003).
Cunnick, J. M. et al. Regulation of the mitogen-activated protein kinase signaling pathway by SHP2. J. Biol. Chem. 277, 9498–9504 (2002).
Jeffers, M., Taylor, G. A., Weidner, K. M., Omura, S. & Vande Woude, G. F. Degradation of the Met tyrosine kinase receptor by the ubiquitin-proteasome pathway. Mol. Cell. Biol. 17, 799–808 (1997).
Peschard, P. et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol. Cell 8, 995–1004 (2001). The authors show that Cbl promotes ubiquitylation of Met. Cbl binds to the active Met receptor at a docking site in the juxtamembrane domain of Met. This docking site is absent in the Trp–Met oncogene.
Hammond, D. E., Urbe, S., Vande Woude, G. F. & Clague, M. J. Down-regulation of MET, the receptor for hepatocyte growth factor. Oncogene 20, 2761–2770 (2001).
Thiery, J. P. Epithelial–mesenchymal transitions in tumour progression. Nature Rev. Cancer 2, 442–454 (2002).
Weidner, K. M., Behrens, J., Vandekerckhove, J. & Birchmeier, W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111, 2097–2108 (1990).
Potempa, S. & Ridley, A. J. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/scatter factor-induced adherens junction disassembly. Mol. Biol. Cell 9, 2185–2200 (1998).
Hartmann, G., Weidner, K. M., Schwarz, H. & Birchmeier, W. The motility signal of scatter factor/hepatocyte growth factor mediated through the receptor tyrosine kinase met requires intracellular action of Ras. J. Biol. Chem. 269, 21936–21939 (1994).
Ridley, A. J., Comoglio, P. M. & Hall, A. Regulation of scatter factor/hepatocyte growth factor responses by Ras, Rac, and Rho in MDCK cells. Mol. Cell. Biol. 15, 1110–1122 (1995). An analysis of the roles of Ras, Rac and Rho in regulating responses to HGF/SF by microinjection of dominant inhibitory proteins. The authors report that inhibition of endogenous Ras proteins prevents HGF/SF-induced actin reorganization, spreading and scattering, and a dominant inhibitor of Rac prevents HGF/SF-induced spreading and actin reorganization.
Khwaja, A., Lehmann, K., Marte, B. M. & Downward, J. Phosphoinositide 3-kinase induces scattering and tubulogenesis in epithelial cells through a novel pathway. J. Biol. Chem. 273, 18793–18801 (1998).
Paumelle, R. et al. Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene 21, 2309–2319 (2002).
Royal, I., Lamarche-Vane, N., Lamorte, L., Kaibuchi, K. & Park, M. Activation of cdc42, rac, PAK, and rho-kinase in response to hepatocyte growth factor differentially regulates epithelial cell colony spreading and dissociation. Mol. Biol. Cell 11, 1709–1725 (2000).
Sakkab, D. et al. Signaling of hepatocyte growth factor/scatter factor (HGF) to the small GTPase Rap1 via the large docking protein Gab1 and the adapter protein CRKL. J. Biol. Chem. 275, 10772–10778 (2000).
Lamorte, L., Kamikura, D. M. & Park, M. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene 19, 5973–5981 (2000).
Fan, S. et al. The multisubstrate adapter Gab1 regulates hepatocyte growth factor (scatter factor)-c-Met signaling for cell survival and DNA repair. Mol. Cell Biol. 21, 4968–4984 (2001).
Xiao, G. H. et al. Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl Acad. Sci. USA 98, 247–252 (2001).
Garcia-Guzman, M., Dolfi, F., Zeh, K. & Vuori, K. Met-induced JNK activation is mediated by the adapter protein Crk and correlates with the Gab1–Crk signaling complex formation. Oncogene 18, 7775–7786 (1999).
Boccaccio, C. et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 391, 285–288 (1998).
Zhang, Y. W., Wang, L. M., Jove, R. & Vande Woude, G. F. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene 21, 217–226 (2002).
Schaper, F. et al. Hepatocyte growth factor/scatter factor (HGF/SF) signals via the STAT3/APRF transcription factor in human hepatoma cells and hepatocytes. FEBS Lett. 405, 99–103 (1997).
Müller, M., Morotti, A. & Ponzetto, C. Activation of NF-κB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol. Cell. Biol. 22, 1060–1072 (2002).
Monga, S. P. et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res. 62, 2064–2071 (2002).
Muller, T., Bain, G., Wang, X. & Papkoff, J. Regulation of epithelial cell migration and tumor formation by β-catenin signaling. Exp. Cell Res. 280, 119–133 (2002).
Orian-Rousseau, V., Chen, L., Sleeman, J. P., Herrlich, P. & Ponta, H. CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev. 16, 3074–3086 (2002).
Giordano, S. et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nature Cell Biol. 4, 720–724 (2002).
Wang, X. et al. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell 9, 411–421 (2002).
Trusolino, L., Bertotti, A. & Comoglio, P. M. A signaling adapter function for α6β4 integrin in the control of HGF-dependent invasive growth. Cell 107, 643–654 (2001).
Crepaldi, T., Gautreau, A., Comoglio, P. M., Louvard, D. & Arpin, M. Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J. Cell Biol. 138, 423–434 (1997).
Schmits, R. et al. CD44 regulates hematopoietic progenitor distribution, granuloma formation, and tumorigenicity. Blood 90, 2217–2233 (1997).
Dowling, J., Yu, Q. C. & Fuchs, E. β4 integrin is required for hemidesmosome formation, cell adhesion and cell survival. J. Cell Biol. 134, 559–572 (1996).
Neyt, C. et al. Evolutionary origins of vertebrate appendicular muscle. Nature 408, 82–86 (2000).
Itoh, M. et al. Role of Gab1 in heart, placenta, and skin development and growth factor- and cytokine-induced extracellular signal-regulated kinase mitogen-activated protein kinase activation. Mol. Cell. Biol. 20, 3695–3704 (2000).
Ieraci, A., Forni, P. E. & Ponzetto, C. Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc. Natl Acad. Sci. USA 99, 15200–15205 (2002).
Maina, F. & Klein, R. Hepatocyte growth factor, a versatile signal for developing neurons. Nature Neurosci. 2, 213–217 (1999).
Dietrich, S. et al. The role of SF/HGF and c-Met in the development of skeletal muscle. Development 126, 1621–1629 (1999).
Michalopoulos, G. K. & DeFrances, M. C. Liver regeneration. Science 276, 60–66 (1997).
Nakamura, T., Mizuno, S., Matsumoto, K., Sawa, Y. & Matsuda, H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J. Clin. Invest. 106, 1511–1519 (2000).
Matsumoto, K. & Nakamura, T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int. 59, 2023–2038 (2001).
Rabkin, R. et al. Hepatocyte growth factor receptor in acute tubular necrosis. J. Am. Soc. Nephrol. 12, 531–540 (2001).
Jin, H. et al. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. J. Pharmacol. Exp. Ther. 304, 654–660 (2003).
Roos, F., Ryan, A. M., Chamow, S. M., Bennett, G. L. & Schwall, R. H. Induction of liver growth in normal mice by infusion of hepatocyte growth factor/scatter factor. Am. J. Physiol. 268, G380–G386 (1995).
Rosen, E. M. & Goldberg, I. D. Regulation of angiogenesis by scatter factor. EXS 79, 193–208 (1997).
Rong, S., Segal, S., Anver, M., Resau, J. H. & Vande Woude, G. F. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl Acad. Sci. USA 91, 4731–4735 (1994). The authors show that NIH-3T3 cells that co-express Met and HGF/SF metastasize in an animal model.
Abounader, R. et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 16, 108–110 (2002).
Takayama, H. et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl Acad. Sci. USA 94, 701–706 (1997).
Danilkovitch-Miagkova, A. & Zbar, B. Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109, 863–867 (2002).
Wang, R., Ferrell, L. D., Faouzi, S., Maher, J. J. & Bishop, J. M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J. Cell Biol. 153, 1023–1034 (2001).
Furge, K. A. et al. Suppression of Ras-mediated tumorigenicity and metastasis through inhibition of the Met receptor tyrosine kinase. Proc. Natl Acad. Sci. USA 98, 10722–10727 (2001).
Ivan, M., Bond, J. A., Prat, M., Comoglio, P. M. & Wynford-Thomas, D. Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells. Oncogene 14, 2417–2423 (1997).
Kitamura, S. et al. Met/HGF receptor modulates bcl-w expression and inhibits apoptosis in human colorectal cancers. Br. J. Cancer 83, 668–673 (2000).
Derksen, P. W. et al. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia 17, 764–774 (2003).
Xin, X. et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Am. J. Pathol. 158, 1111–1120 (2001).
Morotti, A., Mila, S., Accornero, P., Tagliabue, E. & Ponzetto, C. K252a inhibits the oncogenic properties of Met, the HGF receptor. Oncogene 21, 4885–4893 (2002).
Atabey, N. et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J. Biol. Chem. 276, 14308–14314 (2001).
Webb, C. P. et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60, 342–349 (2000).
Schwall, R. & Tabor, K. H. Hepatocyte growth factor receptor antagonists and uses thereof. US Patent 6,468,529 (2002).
Cao, B. et al. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl Acad. Sci. USA 98, 7443–7448 (2001).
Maehara, N. et al. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br. J. Cancer 84, 864–873 (2001).
Longati, P., Comoglio, P. M. & Bardelli, A. Receptor tyrosine kinases as therapeutic targets: the model of the MET oncogene. Curr. Drug Targets 2, 41–55 (2001).
Shawver, L. K., Slamon, D. & Ullrich, A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 1, 117–123 (2002).
Laird, A. D. & Cherrington, J. M. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents. Expert Opin. Investig. Drugs 12, 51–64 (2003).
Druker, B. J. Perspectives on the development of a molecularly targeted agent. Cancer Cell 1, 31–36 (2002).
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Pollack, A. L., Runyan, R. B. & Mostov, K. E. Morphogenetic mechanisms of epithelial tubulogenesis: MDCK cell polarity is transiently rearranged without loss of cell-cell contact during scatter factor/hepatocyte growth factor-induced tubulogenesis. Dev. Biol. 204, 64–79 (1998).
van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
Hay, R. et al. Radioimmunoscintigraphy of tumors autocrine for human Met and hepatocyte growth factor/scatter factor. Mol. Imaging 1, 56–62 (2002).
Shaharabany, M. et al. In vivo molecular imaging of met tyrosine kinase growth factor receptor activity in normal organs and breast tumors. Cancer Res. 61, 4873–4878 (2001).
Jeffers, M. et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl Acad. Sci. USA 94, 11445–11450 (1997).
Hubbard, S. R., Wei, L., Ellis, L. & Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746–754 (1994).
Miller, M. et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 44, 32–43 (2001).
Birchmeier, C. & Brohmann, H. Genes that control the development of migrating muscle precursor cells. Curr. Opin. Cell Biol. 12, 725–730 (2000).
We would like to thank K. Grossmann, H. Wende, H. Brohmann and G. Schütz for the preparation of figures and M. Rosario for helpful discussions. We also thank B. Knudsen, C. Gao, C. Graveel, M. Gustafson, N. Shinomiya, Q. Xie, and Y. Zhang for assistance with Table 1. Finally, we are grateful to M. Reed, R. Hahn, D. Nadziejka, V. Long and S. Olbrich for assistance with the manuscript.
The authors declare no competing financial interests.
- IMMUNOGLOBULIN DOMAIN
A protein domain of ∼90 amino acids consisting of two β-sheets. There are at least 5 distinct structural sets of the domain (V, C1, C2, I and E) that differ in the number, length and position of the strands that compose the two β-sheets.
- KRINGLE DOMAIN
A protein domain of ∼80 amino acids characterized by limited secondary-structure elements and defined by three conserved disulphide bonds.
- SERINE PROTEINASES
Endopeptidases that contain serine, histidine and aspartate in the catalytic site and include the complex, multidomain enzymes of the complement, blood-clotting and fibrinolytic systems. They are synthesized as inactive, single-chain zymogens and converted into active enzymes by site-specific proteolysis.
- HEPARAN-SULPHATE PROTEOGLYCAN
A protein that is bound to a complex polysaccharide (heparan-sulphate glycosaminoglycan) that is present at the cell surface or in the extracellular matrix. When bound to ligand, it can have a key signalling role.
- TYROSINE KINASE DOMAIN
A protein domain with the ability to catalyse the transfer of the γ-phosphate group of ATP to tyrosine residues on protein substrates. Several growth-factor receptors have tyrosine-kinase activity, which triggers a cascade of protein–protein interactions as a result of ligand-induced kinase activation.
- SEMA DOMAIN
A protein domain of ∼450 amino acids identified in the semaphorin axon guidance proteins. Plexins (cell adhesion and semaphorin receptors) and the Met and Ron receptors also contain the sema domain or a variant of it. The sema domain of the Met receptor and of semaphorins adopts a β-propeller fold.
- SH3 DOMAIN
(Src-homology-domain 3). A protein sequence of about 50 amino acids that recognizes and binds sequences rich in proline.
- SH2 DOMAIN
(Src-homology-2 domain). A protein motif that recognizes and binds tyrosine-phosphorylated sequences, and thereby has a key role in relaying cascades of signal transduction.
- PLECKSTRIN-HOMOLOGY (PH) DOMAIN
A sequence of 100 amino acids that is present in many signalling molecules and binds to lipid products of phosphatidylinositol 3-kinase. Pleckstrin is a protein of unknown function that was originally identified in platelets and is a principal substrate of protein kinase C.
- E3 UBIQUITIN PROTEIN LIGASE
The third enzyme in a series — the first two are designated E1 and E2 — that is responsible for ubiquitylation of target proteins. E3 enzymes provide platforms for binding E2 enzymes and specific substrates, thereby coordinating ubiquitylation of the selected substrates.
- EPITHELIAL–MESENCHYMAL TRANSITION
The transformation of an epithelial cell into a mesenchymal cell with migratory and invasive properties.
- ETS/AP1 TRANSCRIPTION FACTOR
A bipartite transcription-regulatory element.
- PLACENTAL TROPHOBLAST
The inner trophoblastic layer of cells that gives rise to the syncytiotrophoblast, which faces the maternal circulation and constitutes a layer through which all substances must pass from the mother to the fetus.
Epithelial-cell layer in the dorsolateral region of the somite that faces the ectoderm and further differentiates into the most dorsal dermatome, which later differentiates into dermis and myotome — future skeletal muscles.
A mesodermal ball of cells adjacent to the neural tube that will differentiate into the muscle, vertebrae and dermis.
- NEURAL CREST CELLS
A group of embryonic cells that separate from the embryonic neural plate and migrate, giving rise to the spinal and autonomic ganglia, peripheral glia, chromaffin cells, melanocytes and some haematopoietic cells.
- NUDE MICE
Mice that have a mutation causing both hairlessness and defective formation of the thymus, which results in a lack of mature T cells.
A malignant tumour of the bone. It usually develops during the period of rapid growth during adolescence.
A malignant tumour of epithelial origin.
- GLIOBLASTOMA MULTIFORME
A poorly differentiated, rapidly growing brain tumour that occurs most often in adults.
A low-molecular-weight compound that binds to heat-shock protein 90 (Hsp90), a highly conserved cytosolic protein in eukaryotic and prokaryotic cells that functions as a chaperone. Geldanamycin inhibits Hsp90 function, which causes the proteasomal degradation of proteins that require the chaperone for maturation or stability. Geldanamycin therefore destabilizes proteins, such as Met, ErbB2, Bcr–Abl, or Akt/PKB, and can suppress tumour formation in animal models.
- NUCLEAR IMAGING
The generation and analysis of diagnostic images showing the interaction of a radioactive compound with particular organs or tissues.
The use of radiolabelled antibodies or antibody derivatives for nuclear imaging.
A site-specific recombination system derived from the Escherichia coli bacteriophage P1. Two short DNA sequences (loxP sites) are engineered to flank the target DNA. Activation of the Cre recombinase enzyme catalyses recombination between the loxP sites, which leads to the excision of the intervening sequence.
About this article
Cite this article
Birchmeier, C., Birchmeier, W., Gherardi, E. et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4, 915–925 (2003). https://doi.org/10.1038/nrm1261
Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-Met-targeted probe in a preclinical xenograft model
Journal of Controlled Release (2021)
Seminars in Cancer Biology (2021)
Cancer Science (2021)
WIREs Nanomedicine and Nanobiotechnology (2021)